表紙
市場調査レポート

小細胞肺がん治療薬の世界市場:2015年〜2019年

Global Small Cell Lung Cancer Therapeutics Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 326315
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
小細胞肺がん治療薬の世界市場:2015年〜2019年 Global Small Cell Lung Cancer Therapeutics Market 2015-2019
出版日: 2015年03月18日 ページ情報: 英文 102 Pages
概要

肺がんは、非小細胞肺がんと小細胞肺がんの2種類に分けることができます。小細胞肺がんは、肺がんと診断された全症例の約10〜15%を占めています。世界の小細胞肺がん治療薬市場は、2014年〜2019年のCAGRで、3.6%の成長が見込まれています。

当レポートでは、世界の小細胞肺がん治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 疾患の概要

  • 疾患について
  • 分類
  • 診断
  • 発症率と患者数
  • 病期
  • 管理
  • 経済的負担

第6章 イントロダクション

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • 主要予測
  • ファイブフォース分析

第8章 パイプライン分析

  • パイプライン候補に関する主要情報
  • 開発中の主要製品のタイムライン

第9章 市場区分:薬効分類別

  • アルキル化剤
  • 代謝拮抗剤
  • 微小管阻害剤
  • 細胞傷害性抗生物質
  • トポイソメラーゼ阻害剤
  • その他

第10章 市場区分:投与経路別

  • 経口
  • 非経口

第11章 市場区分:剤形別

  • 固体
  • 液体

第12章 地域区分

  • 南北アメリカの小細胞肺がん市場
    • 市場規模と予測
  • 欧州・中東・アフリカ地域の小細胞肺がん市場
    • 市場規模と予測
  • アジア太平洋地域の小細胞肺がん市場
    • 市場規模と予測

第13章 購入基準

第14章 市場成長促進要因

第15章 成長促進要因とその影響

第16章 市場の課題

第17章 成長促進要因と課題の影響

第18章 市場動向

第19章 動向とその影響

第20章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第21章 主要ベンダーの分析

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Menarini
  • Sanofi
  • ZIOPHARM Oncology

第22章 関連レポート

図表

目次
Product Code: IRTNTR5579

About Small Cell Lung Cancer

Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.

TechNavio's analysts forecast the Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.60 percent over the period 2014-2019.

Covered in this Report

TechNavio's report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Menarini
  • Sanofi
  • ZIOPHARM Oncology

Other Prominent Vendors

  • Alchemia
  • Amgen
  • Apotex
  • BioMarin Pharmaceutical
  • CellAct Pharma
  • Cerulean Pharma
  • Cipla
  • Cornerstone Pharmaceuticals
  • Curis
  • CytRx
  • Eli Lilly
  • Exelixis
  • Fresenius Kabi
  • Genentech
  • Hikma Pharmaceuticals
  • Hospira
  • Intas Pharmaceuticals
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Ligand Pharmaceuticals
  • Lundbeck
  • MabVax Therapeutics Holdings
  • Medac Pharma
  • MEI Pharma
  • Merck
  • MolMed
  • Mologen
  • Mylan
  • Nektar Therapeutics
  • Neotropix
  • Novartis
  • Novogen
  • OncoMed Pharmaceuticals
  • Ono Pharmaceutical
  • PharmaMar
  • Polaris Group
  • Sagent Pharmaceuticals
  • Shanghai Jinhe Bio-Technology
  • Spectrum Pharmaceuticals
  • STADA Arzneimittel
  • Stem CentRx
  • Sun Pharmaceuticals Industries
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Zydus Cadila Healthcare

Market Driver

  • High Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Treatment
  • For a full, detailed list, view our report

Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

  • 05.1. Understanding the Disease
  • 05.2. Classification
    • 05.2.1. Small Cell Carcinoma
    • 05.2.2. Combined Small Cell Carcinoma
  • 05.3. Diagnosis
    • 05.3.1. Physical Examination
    • 05.3.2. Laboratory Tests
    • 05.3.3. Chest X-ray
    • 05.3.4. Sputum Cytology
    • 05.3.5. CT Scan
    • 05.3.6. Biopsy
    • 05.3.7. Light and Electron Microscopy
    • 05.3.8. Immunohistochemistry
  • 05.4. Rate of Incidence and Prevalence
  • 05.5. Staging
  • 05.6. Management
  • 05.7. Economic Burden

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Top Predictions
  • 07.4. Five Forces Analysis

08. Pipeline Analysis

  • 08.1. Key Information on the Pipeline Candidates
    • 08.1.1. Palifosfamide (ZIO-201)
    • 08.1.2. Ipilimumab+Etoposide+Cisplatin/Carboplatin
    • 08.1.3. Ipilimumab
    • 08.1.4. Enoxaparin Sodium
    • 08.1.5. BAY1000394 (Roniciclib)
    • 08.1.6. Nivolumab (ONO-4538/ BMS-936558)
    • 08.1.7. BMS-986012
    • 08.1.8. LY2940680
    • 08.1.9. Sabarubicin (MEN 10755)
    • 08.1.10. CAP7.1
    • 08.1.11. SC16LD6.5
    • 08.1.12. BIW-8962
    • 08.1.13. AMG 479 (Ganitumab)
    • 08.1.14. LY2510924
    • 08.1.15. Trisenox
    • 08.1.16. MGN1703
    • 08.1.17. Tarextumab (OMP-59R5)
    • 08.1.18. BMN 673 (Talazoparib Tosylate)
    • 08.1.19. NGR-hTNF
    • 08.1.20. CPI-613
    • 08.1.21. Alisertib (MLN8237)
    • 08.1.22. Vismodegib (GDC-0449, Erivedge)
    • 08.1.23. Cabozantinib (XL184 or Cometriq)
    • 08.1.24. Selinexor (KPT-330)
    • 08.1.25. ADI-PEG 20 (Pegargiminase)
    • 08.1.26. Etirinotecan Pegol (NKTR-102)
    • 08.1.27. CRLX101 (IT-101 or Cyclodextrin-based Polymer-camptothecin IT-101)
    • 08.1.28. NTX-010
    • 08.1.29. Aldoxorubicin
    • 08.1.30. HA-Irinotecan
    • 08.1.31. Carfilzomib
    • 08.1.32. Small Cell Lung Cancer Vaccine
    • 08.1.33. GSK2879552
    • 08.1.34. NV-344 (ME-344)
    • 08.1.35. BMS-833923 (XL139)
    • 08.1.36. PM01183 (Lurbinectedin)
    • 08.1.37. LDE225 (Erismodegib or Sonidegib)
    • 08.1.38. Belinostat
  • 08.2. Timeline for Major Products under Development
    • 08.2.1. Palifosfamide (ZIO-201)
    • 08.2.2. Sabarubicin (MEN 10755)

09. Market Segmentation by Therapeutic Class of Drugs

  • 09.1. Alkylating Agents
  • 09.2. Antimetabolites
  • 09.3. Microtubule Inhibitors
  • 09.4. Cytotoxic Antibiotics
  • 09.5. Topoisomerase Inhibitors
  • 09.6. Others

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Market Segmentation by Dosage Form

  • 11.1. Solid
  • 11.2. Liquid

12. Geographical Segmentation

  • 12.1. Small Cell Lung Cancer Market in Americas
    • 12.1.1. Market Size and Forecast
  • 12.2. Small Cell Lung Cancer Market in EMEA Region
    • 12.2.1. Market Size and Forecast
  • 12.3. Small Cell Lung Cancer Market in APAC Region
    • 12.3.1. Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Bristol-Myers Squibb
    • 20.2.2. GlaxoSmithKline
    • 20.2.3. Menarini
    • 20.2.4. Sanofi
    • 20.2.5. ZIOPHARM Oncology
  • 20.3. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Bristol-Myers Squibb
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Key Product Offerings
    • 21.1.4. Revenue by Geography
    • 21.1.5. Business Strategy
    • 21.1.6. Key Information
    • 21.1.7. SWOT Analysis
  • 21.2. GlaxoSmithKline
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Pipeline Products
    • 21.2.7. Business Strategy
    • 21.2.8. Key Information
    • 21.2.9. SWOT Analysis
  • 21.3. Menarini
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Key Pipeline Products
    • 21.3.4. Recent Developments
    • 21.3.5. SWOT Analysis
  • 21.4. Sanofi
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis
  • 21.5. ZIOPHARM Oncology
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Recent Developments
    • 21.5.4. SWOT Analysis

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Classification of Lung Cancer
  • Exhibit 3: Techniques for Diagnosing Small Cell Lung Cancer
  • Exhibit 4: Incidence of Lung Cancer in WHO Regions
  • Exhibit 5: Staging of Small Cell Lung Cancer
  • Exhibit 6: Small Cell Lung Cancer by Stage
  • Exhibit 7: Five-year Survival Rate of Small Cell Lung Cancer Patients
  • Exhibit 8: Stepwise Diagrammatic Representation of Management of Small Cell Lung Cancer (According to ESMO Guidelines)
  • Exhibit 9: Global Small Cell Lung Cancer Therapeutics Market 2014-2019 (US$ million)
  • Exhibit 10: Top Predictions in Global Small Cell Lung Cancer Therapeutics Market
  • Exhibit 11: Pipeline Portfolio of Small Cell Lung Cancer Drugs
  • Exhibit 12: Timeline of Palifosfamide (ZIO-201)
  • Exhibit 13: Timeline of Sabarubicin (MEN 10755)
  • Exhibit 14: Global Small Cell Lung Cancer Therapeutics Market by Therapeutic Class of Drugs
  • Exhibit 15: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration
  • Exhibit 16: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration 2014
  • Exhibit 17: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms
  • Exhibit 18: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms 2014
  • Exhibit 19: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2014
  • Exhibit 20: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2019
  • Exhibit 21: Small Cell Lung Cancer Therapeutics Market in Americas 2014-2019 (US$ million)
  • Exhibit 22: Small Cell Lung Cancer Therapeutics Market in EMEA Region 2014-2019 (US$ million)
  • Exhibit 23: Small Cell Lung Cancer Therapeutics Market in APAC Region 2014-2019 (US$ million)
  • Exhibit 24: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 25: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
  • Exhibit 26: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 27: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 28: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 29: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 30: Menarini: Key Pipeline Products
  • Exhibit 31: Sanofi SA: Business Segmentation
  • Exhibit 32: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 33: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 34: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top